How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis.

Abstract

BACKGROUND\nOpioid prescribing, for chronic non-cancer pain, has increased substantially in the past two decades and is associated with significant harms. Various public health approaches have been adopted to address these harms including the implementation of prescription drug monitoring programs (PDMPs). This systematic review aims to identify how PDMP use influences healthcare providers clinical decision-making.\n\n\nMETHODS\nSix databases were searched for literature up until April 2021. Empirical studies were included, with no restrictions placed on year, location, language or study design. Thematic analysis of the identified articles was conducted and where possible, meta-analyses were conducted using a random effect model in Stata.\n\n\nRESULTS\nForty-one articles related to 39 studies were included. All studies were conducted in the United States, published between 2005 and 2021 and most (n\xa0=\xa028) related to one state-level PDMP. PDMP utilisation influenced healthcare providers clinical decision-making across seven broad themes: (i) the supply of controlled substances, (ii) refusal to prescribe or treat, (iii) risk mitigation strategies, (iv) communication, (v) education and counselling, (vi) referrals and care coordination and (vii) stigma.\n\n\nCONCLUSIONS\nPDMP use influenced healthcare providers clinical decision-making, resulting in both intended and unintended outcomes for patients. PDMPs are a public health initiative designed to reduce harms associated with increased opioid prescribing, yet their use is associated with multiple unintended outcomes. Targeted research is needed to understand the impact of healthcare providers clinical decision-making after PDMP utilisation, and the clinical outcomes for patients identified through these tools.